William Blair Investment Management LLC lessened its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 4.6% in the third quarter, Holdings Channel.com reports. The fund owned 246,345 shares of the specialty pharmaceutical company’s stock after selling 11,828 shares during the quarter. William Blair Investment Management LLC’s holdings in ANI Pharmaceuticals were worth $17,897,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. KBC Group NV bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at $28,000. Versant Capital Management Inc lifted its stake in shares of ANI Pharmaceuticals by 103.3% in the 3rd quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 217 shares during the period. Eurizon Capital SGR S.p.A. acquired a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at $32,000. USA Financial Formulas bought a new position in shares of ANI Pharmaceuticals in the 3rd quarter worth $39,000. Finally, Sterling Capital Management LLC boosted its position in shares of ANI Pharmaceuticals by 850.0% in the 3rd quarter. Sterling Capital Management LLC now owns 684 shares of the specialty pharmaceutical company’s stock worth $50,000 after purchasing an additional 612 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.
Insider Activity
In other news, CEO Nikhil Lalwani sold 5,400 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $71.00, for a total value of $383,400.00. Following the completion of the transaction, the chief executive officer owned 339,089 shares of the company’s stock, valued at $24,075,319. The trade was a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Carey sold 2,850 shares of the company’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $72.87, for a total transaction of $207,679.50. Following the completion of the sale, the chief financial officer owned 166,143 shares of the company’s stock, valued at approximately $12,106,840.41. This represents a 1.69% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 27,250 shares of company stock worth $1,975,156 over the last quarter. Corporate insiders own 8.10% of the company’s stock.
ANI Pharmaceuticals Price Performance
Shares of NASDAQ ANIP opened at $71.44 on Monday. ANI Pharmaceuticals, Inc. has a 52-week low of $67.14 and a 52-week high of $87.76. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.33 and a current ratio of 2.75. The stock has a market cap of $1.62 billion, a P/E ratio of 14.23, a P/E/G ratio of 2.30 and a beta of 0.45. The firm has a 50 day moving average price of $72.32 and a 200 day moving average price of $77.00.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last posted its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.18 by $0.52. The company had revenue of $290.78 million for the quarter, compared to analyst estimates of $280.59 million. ANI Pharmaceuticals had a net margin of 11.22% and a return on equity of 28.34%. The business’s revenue for the quarter was up 27.6% compared to the same quarter last year. During the same period last year, the business posted $2.04 earnings per share. Analysts expect that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current year.
Analyst Upgrades and Downgrades
ANIP has been the subject of a number of analyst reports. Guggenheim lifted their price objective on ANI Pharmaceuticals from $119.00 to $121.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Oppenheimer began coverage on ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 target price on the stock. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Wednesday, November 4th. Finally, Canaccord Genuity Group decreased their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $100.00.
Get Our Latest Stock Report on ANI Pharmaceuticals
ANI Pharmaceuticals Profile
ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.
See Also
- Five stocks we like better than ANI Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
